Boehringer Ingelheim Launches Fast-acting Stroke Medication in the UAE, Reducing Treatment Administration to Five Seconds
Health Web Release Selection By Editor_wr On Feb 27, 2025
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has launched a new acute ischemic stroke (AIS) medication with active ingredient Tenecteplase 25mg to enhance emergency stroke treatment in the UAE, offering a faster and more effective treatment option for emergency stroke care. Launched in the UAE for the first time across the India, Middle East, Turkey and Africa region, the new medication can be delivered over five to ten seconds, compared to the previous treatments requiring a one-hour administration process. This simplified and rapid approach facilitates faster treatment administration in emergency settings, reducing both door-to-needle (DTN) times and door-in-door-out (DIDO) times. This can improve patient recovery outcomes and minimize long-term neurological deficits associated with stroke . Stroke is the second leading cause of death globally and a major contributor to disability, thereby imposing significant burdens on both patients and the economy . Many survivors face long-term disabilities, with up to 50% being chronically disabled . In the UAE, between 8,000 to 10,000 individuals suffer from a stroke each year, which amounts to one case every hour . Ischemic strokes occur when there is a blockage in a blood vessel, resulting in reduced blood supply to the brain . Early recognition of symptoms is crucial for effective treatment. Common signs include sudden numbness or weakness, especially on one side of the body; confusion or trouble speaking; difficulty seeing in one or both eyes; dizziness or loss of balance; and a severe headache with no known cause . The new medication was launched on 22 February during the 5th Dubai Neurology Congress, which brought together over 120 healthcare professionals from the UAE. Dr. Suhail Al Rukn, President of the Emirates Neurology Society and Consultant Neurologist highlighted the importance of time efficiency in stroke care. 'Time is brain,' Dr. Al Rukn said. 'Reducing the time between symptoms onset and treatment is crucial in saving lives and preserving brain function . For every minute that treatment is delayed, millions of brain cells are lost . Seeking immediate medical care can therefore greatly improve outcomes and minimize the risk of long-term disability. This new treatment offers a major leap forward by minimizing delays and simplifying the administration process, providing an opportunity to improve outcomes for stroke patients in the UAE.' Ousama Alhaj, General Manager and Head of Human Pharma, Boehringer Ingelheim in the Near East and UAE added: 'The UAE, like many other countries around the world, faces a growing incidence of stroke cases each year , making timely treatment a priority. This new medication not only improves the efficiency of care delivery but also enhances the overall healthcare journey for patients. At Boehringer Ingelheim, we are committed to developing patient-centered health solutions that improve survival rates and long-term outcomes for stroke patients. We also remain committed to working closely with healthcare stakeholders to ensure these medications are accessible to those who need them.'
Administered at a dose of 0.25mg/kg (up to a maximum of 25mg) as a single intravenous bolus, the new treatment is now available in the UAE and underscores Boehringer Ingelheim's ongoing dedication to patient-centered innovation in healthcare, with a focus on early detection, prevention, and treatment. The company continues to strengthen its presence in the UAE by providing advanced medical solutions that address the needs of healthcare professionals and patients alike.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
5 days ago
- Zawya
DoH and Boehringer Ingelheim Ink strategic partnership to advance life science innovation across the Emirate
Abu Dhabi, United Arab Emirates: The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim, one of the world's leading research-driven pharmaceutical companies. This strategic partnership aims to advance scientific research and innovation, foster groundbreaking research and development and cultivate an environment of scientific excellence, further cementing the Emirate as the MENA region's premier hub for healthcare, life sciences and innovation. In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at BI, the agreement was signed during BIO International Convention in Boston at the Abu Dhabi Pavilion by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at BI. Through this strategic partnership, the two parties seek to strengthen the Emirate's research ecosystem by facilitating access to and harnessing the capabilities of Boehringer Ingelheim'sOpnME platform. Researchers, scientists and innovators across Abu Dhabi will be able to leverage the platform's cutting-edge data and resources to address critical biological challenges and accelerate scientific discovery. Through four flagship programmes, Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e) and opnTALENTS (o25), the platform empowers the research community with access to advanced compounds, collaborative opportunities, expert networks and support for emerging talent. OpnME connects visionary researchers to champion transformative, research-driven medical innovation for generations to come. In line with Abu Dhabi's vision to shape the future of healthcare, this partnership between DoH and BI enhances knowledge exchange and invests in local talent. It offers scientists a purpose-driven, globally connected environment to lead impactful research, further reinforcing the Emirate's commitment to transforming the regional healthcare ecosystem through science and technology. Dr. Asma Ibrahim Al Mannaei, the Executive Director of the Health Life Sciences Sector at DoH, said: 'Our partnership with Boehringer Ingelheim reflects our commitment to pioneering innovation and scientific research as parts of our efforts to advance health outcomes and improve the quality of life for communities around the world. We're empowering Abu Dhabi researchers with the opnMe platform, an open portal offering top-tier pharmaceutical compounds, fostering collaboration and safeguarding researchers' rights to their findings. This is about transforming our emirate into a global life sciences hub, speeding up breakthroughs, and building a healthier, resilient future for all.' Ousama Alhaj, General Manager and Head of Human Pharma for Near East and UAE at Boehringer Ingelheim, said: 'At Boehringer Ingelheim, we are proud to partner with the Department of Health – Abu Dhabi (DoH) to empower the scientific community through our OpnMe platform. This collaboration reflects our shared commitment to advancing research and innovation in the region, fostering a culture of discovery, and ultimately improving patient outcomes. By providing access to our scientific resources, including advanced compounds, collaborative research opportunities, and expert networks, we aim to inspire new ideas and support the next generation of researchers in Abu Dhabi.' Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 14 to 21, delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, startAD and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual.
Al Etihad
5 days ago
- Al Etihad
Department of Health - Abu Dhabi, Boehringer Ingelheim ink strategic partnership
17 June 2025 13:56 ABU DHABI (WAM) The Department of Health - Abu Dhabi (DoH) signed a Memorandum of Understanding with Boehringer Ingelheim, one of the world's leading research-driven pharmaceutical strategic partnership aims to advance scientific research and innovation, foster groundbreaking research and development, and cultivate an environment of scientific excellence, further cementing the emirate as the MENA region's premier hub for healthcare, life sciences, and the presence of Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at BI, the agreement was signed during BIO International Convention in Boston at the Abu Dhabi Pavilion by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at this strategic partnership, the two parties seek to strengthen the Emirate's research ecosystem by facilitating access to and harnessing the capabilities of Boehringer Ingelheim's OpnME scientists, and innovators across Abu Dhabi will be able to leverage the platform's cutting-edge data and resources to address critical biological challenges and accelerate scientific four flagship programmes, Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e) and opnTALENTS (o25), the platform empowers the research community with access to advanced compounds, collaborative opportunities, expert networks, and support for emerging connects visionary researchers to champion transformative, research-driven medical innovation for generations to Mannaei said, 'Our partnership with Boehringer Ingelheim reflects our commitment to pioneering innovation and scientific research as part of our efforts to advance health outcomes and improve the quality of life for communities around the empowering Abu Dhabi researchers with the opnMe platform, an open portal offering top-tier pharmaceutical compounds, fostering collaboration and safeguarding researchers' rights to their findings. This is about transforming our emirate into a global life sciences hub, speeding up breakthroughs, and building a healthier, resilient future for all.' Alhaj said, 'At Boehringer Ingelheim, we are proud to partner with the Department of Health – Abu Dhabi (DoH) to empower the scientific community through our OpnMe platform. This collaboration supports research, innovation, and the next generation of researchers in the region.'
Zawya
15-06-2025
- Zawya
The 5th International Neuroscience Summit for the Middle East, Africa and Russia is being held in Dubai
Saudi Arabia - The International Neurology Conference for the Middle East, Africa and Russia kicked off in Dubai, in cooperation with AbbVie, the global biopharmaceutical research and development company, with the participation of an elite group of international and national speakers and in the presence of several consultants, specialist physicians, researchers, professors and neurology experts from Gulf countries, Saudi Arabia, Egypt and Russia, in addition to several international, regional and local medical associations. The conference included several scientific lectures that discuss the latest research and treatment methods for many neurological diseases such as Parkinson's disease, migraine and post-stroke spasticity. Dr. Abdulrazzaq Al-Bilali, Headache Specialist and Head of the Saudi Headache Chapter, Saudi Neurology Society, commended the continuous efforts of the organizers of this major conference and its success for the fifth consecutive year. Dr. Abdulrazzaq emphasized that scientific research is the cornerstone of progress in the field of neurology. He explained that headache is a health problem that significantly impacts people's lives and daily activities, and that significant developments have occurred in diagnostic methods and disease management. He emphasized that the future of patient care lies in innovation and evidence-based knowledge. For his part, Dr. Suhail Al Rukun, consultant neurology, President of Emirates neurology Society in the United Arab Emirates, praised the large turnout at the conference, which included valuable medical discussions, workshops, and a review of the latest recommendations from clinical trials and research in this sector, in addition to presenting the best methods used in the management of patients with neurological diseases. Dr. Suhail added that this prominent scientific event is a good opportunity to exchange experiences and keep up with the latest developments in the neurology field. Organizing this summit for the fifth consecutive year embodies the ongoing commitment to enhancing medical knowledge and achieving the best treatment outcomes for patients. These initiatives help improve the quality of healthcare and open new horizons for improving patients' lives. Mohammad Aboubakr, Vice President and General Manager of AbbVie's Middle East, Africa & Russia region, commended the launch of the fifth Neurology Summit, which highlighted the latest emerging scientific and medical developments. He emphasized that organizing the summit reflects AbbVie's commitment to enhancing scientific training and research programs and providing a high level of medical care to serve society members by providing what helps improve their quality of life. The company seeks to help make a real difference in patients' lives, as well as its commitment to raising awareness and health education for patients, and on the other hand, its focus on the fields of education, training and scientific research. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
